ABS 1230
Alternative Names: ABS-1230Latest Information Update: 26 Sep 2025
At a glance
- Originator Actio Biosciences
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action KCNT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Epilepsy
Most Recent Events
- 23 Sep 2025 Phase-I clinical trials in Epilepsy (In volunteers, In adults) in Australia (PO) (NCT07156201)
- 23 Sep 2025 US FDA with Ethics Committee approves IND application for ABS 1230 in Epiliepsy, before September 2025
- 23 Sep 2025 Actio Biosciences plans a proof-of-concept phase Ib/IIa trial for Epilepsy in US in early 2026